Five IIDR members awarded more than $14M in federal grants

The grants, which will support cutting-edge research ranging from the discovery of novel antibiotics to the development of a global vaccination strategy to control Tuberculosis (TB), are part of a larger $667M investment from two of the federal agency's funding competitions.

August 23, 2016

CIHR_1

Experts Featured In This Story

Mark Loeb
Mark Loeb

Professor

See Profile
Karen Mossman
Karen Mossman

Professor

See Profile
Zhou Xing
Zhou Xing

Professor

See Profile

Five research programs led by members of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) will receive more than $14M from the .
The grants, which will support cutting-edge research ranging from the discovery of novel antibiotics to the development of a global vaccination strategy to control Tuberculosis (TB), are part of a

Five research programs led by members of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) will receive more than $14M from the Canadian Institutes of Health Research (CIHR).

The grants, which will support cutting-edge research ranging from the discovery of novel antibiotics to the development of a global vaccination strategy to control Tuberculosis (TB), are part of a larger $667M investment from two of the federal agency’s funding competitions.

CIHR Foundation Grant awards

Established in 2015, the Foundation Grant competition provides long-term support of five to seven years for the pursuit of innovative, high-impact research programs.

  • Gerry Wright, professor in the department of Biochemistry and Biomedical Sciences and scientific director of the IIDR, will receive $4,246,166 to address the antibiotic resistance crisis. Wright’s work will focus on the mechanisms and origins of drug resistance and the discovery of new antibiotics and antimicrobial strategies.

CIHR Project Grant awards 

The Project Grant competition provides short- and long-term support of one to five years to advance health-related knowledge, health research, health care, health systems, and/or health outcomes. 

  • Zhou Xing, professor in the department of Pathology and Molecular Medicine, will receive $875,355 to develop a new Tuberculosis (TB) vaccination strategy that will ultimately contribute to the effective control of lung TB around the world.
  • Karen Mossman, professor in the department of Pathology and Molecular Medicine, will receive $688,051 to discover and develop novel, generic antiviral therapies capable of protecting against new, emerging viruses.
  • Mike Surette, professor in the department of Medicine, will receive $653,649 to advance his studies of the human microbiome for the discovery of novel antibiotics, immunomodulators and probiotics.
Three scientists standing together in a laboratory. Two are holding small bottles.

New drug candidate reverses metabolic liver disease and fibrosis, pre-clinical data shows

The findings point to a potential new treatment for millions of people, addressing a critical gap where no approved drugs exist in Canada.
A smiling person in the background, with their hand holding a vial of medicine in the foreground.

‘Helper molecule’ discovery offers new hope against drug-resistant fungal infections

Postdoc’s painstaking sleuthing yields the Wright Lab’s third groundbreaking antimicrobial discovery in a year.
Two smiling people working at a computer in a lab. One is wearing a lab coat.

How McMaster is advancing healthy aging through research, partnerships and impact

‘Aging doesn’t happen in silos.’ At the McMaster Institute for Research on Aging, researchers from all faculties work together to study the complex, interconnected factors affecting how we age.